'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"'No discussions' over AstraZeneca-Bristol Myers deal, senior source says" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Fierce Pharma, Endpoints News and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 79d ago.
Quick answers
Why is "'No discussions' over AstraZeneca-Bristol Myers deal, senior source says" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- AstraZeneca may buck a decade of pharma strategy to buy U.S. scale cnbc.com · 79d ago
- Deal or No Deal, AstraZeneca Stock Is a Bargain WSJ · 79d ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger BioSpace · 79d ago
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks Yahoo Finance · 79d ago
- Soriot should explain the curious case of AstraZeneca’s non-deal The Guardian · 79d ago
- ‘No discussions’ ongoing for AstraZeneca-Bristol Myers merger: Reuters Fierce Pharma · 79d ago
- Merger talks between AstraZeneca, Bristol Myers are off Endpoints News · 79d ago
- 'No discussions' over AstraZeneca-Bristol Myers deal, senior source says Reuters · 79d ago
Topics
Related trends
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers Squibb halt autoimmune CAR-T trials following patient deaths, impacting the sector.
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.
Seahawks Droppings: Jason Myers meltdown cements Seattle’s winless preseason
Seattle Seahawks kicker Jason Myers missed a final-play field goal, leaving the team winless after a 9-9 preseason tie with the Kansas City Chiefs.
Seahawks-Chiefs instant video reaction: Milroe impresses, but Jason Myers worries
A 9‑9 preseason tie leaves Seahawks and Chiefs weighing a missed kick and a rookie’s flash of promise.
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.